Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...

Hims & Hers (NYSE:HIMS) has launched an online GLP-1 supply tracker where people can share information about where the ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Subscriber growth surged 44% y/y to 2.05 million. It's also worth noting that ex-GLP 1 subgrowth would have been 40% y/y, ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Even without the contribution from GLP-1 drugs, revenue growth would have soared. The stock is cheap given the company's revenue growth and margins. Hims & Hers strong performance involves much ...

Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

Analysts are buzzing as well, with TD Cowen raising its price target to $28, citing HIMS' diverse revenue streams and minimal ...